KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Acadia Pharmaceuticals (ACAD) Accumulated Depreciation & Amortization (2016 - 2025)

Acadia Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 15 years, most recently at $9.5 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $9.5 million for Q4 2025, down 7.17% from a year ago — trailing twelve months through Dec 2025 was $9.5 million (down 7.17% YoY), and the annual figure for FY2025 was $9.5 million, down 7.17%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $9.5 million at Acadia Pharmaceuticals, down from $10.2 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for ACAD hit a ceiling of $10.2 million in Q4 2024 and a floor of $6.2 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $9.5 million (2025), compared with a mean of $8.7 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 56.64% in 2021 and later decreased 7.17% in 2025.
  • Acadia Pharmaceuticals' Accumulated Depreciation & Amortization stood at $6.2 million in 2021, then skyrocketed by 30.93% to $8.1 million in 2022, then increased by 18.02% to $9.6 million in 2023, then grew by 6.92% to $10.2 million in 2024, then decreased by 7.17% to $9.5 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $9.5 million (Q4 2025), $10.2 million (Q4 2024), and $9.6 million (Q4 2023) per Business Quant data.